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Open reading frame 2 (ORF2) of porcine circovirus type 2 (PCV2) codes for the 233-amino-acid capsid
protein (CP). Baculovirus-based vaccines that express only ORF2 are protective against clinical disease
following experimental challenge or natural infection. The goal of this study was to identify regions in CP
preferentially recognized by sera from experimentally infected and vaccinated pigs and to compare these
responses to those of pigs diagnosed with porcine circovirus-associated disease (PCVAD), including porcine
multisystemic wasting syndrome (PMWS) and porcine dermatitis and nephropathy syndrome (PDNS). The
approach was to react porcine sera with CP polypeptide fragments followed by finer mapping studies using
overlapping oligopeptides that covered amino acids 141 to 200. The results showed that vaccinated pigs
preferentially recognized only the largest polypeptide fragment, CP(43–233). A subset of experimentally
infected pigs and pigs with PDNS showed strong reactivity against a CP oligopeptide, 169-STIDYFQPNNKR-
180. Alanine scanning identified Y-173, F-174, Q-175, and K-179 as important for antibody recognition. The
results from this study support the notion of PCV2 modulation of immunity, including antibody responses that
may represent a precursor for disease. The recognition of CP(169–180) and other polypeptides provides
opportunities to devise diagnostic tests for monitoring the immunological effectiveness of vaccination.
First described in Canada in the early 1990s, porcine circo-
virus-associated disease (PCVAD) has emerged as an econom-
ically important disease worldwide (1, 48). A central feature of
PCVAD is the involvement of porcine circovirus type 2
(PCV2). PCVAD encompasses a group of complex, multifac-
torial diseases, of which porcine multisystemic wasting syn-
drome (PMWS) and porcine dermatitis and nephropathy syn-
drome (PDNS) are common syndromes (7, 49, 52, 53). Even
though Krakowka et al. (25) reported the appearance of PDNS
in gnotobiotic pigs in the absence of PCV2, pigs with clinical
PDNS possess high levels of PCV2-specific antibodies, which
are implicated in disease progression (53). In 2008, poor
growth performance in herds without overt clinical signs was
reported as another manifestation of PCVAD (20). Factors
such as host genetics, other infectious agents, and the patho-
genic potential of the PCV2 isolate contribute to the disease
(2, 3, 14, 23, 24, 40, 41, 43).
The majority of PCV2 isolates can be divided into one of two
genotypes, known as PCV2a and PCV2b (11, 19, 39). A third
genotype, designated PCV2c, describes a small group of his-
torical isolates found in Denmark (48). The genotypic classi-
fication of PCV2 is complicated by field isolates composed of
PCV2a and PCV2b sequences (18, 32). The PCV2 genome is
dominated by three open reading frames (ORFs). The 233-
amino-acid capsid protein (CP), coded for by ORF2, forms a
homopolymer that surrounds the single-stranded ambisense
1.7-kb DNA genome (38). The principal sequence differences
between PCV2a and PCV2b genotypes localize to ORF2,
where the nucleotide and peptide sequence identities are ap-
proximately 93%. Baculovirus-based vaccines that express
PCV2 ORF2 are sufficient to offer protection from disease (4,
15, 19, 31, 42, 51). ORF1 is 945 nucleotides (nt) in length and
codes for two replicase proteins, Rep and Rep (12, 34). A
third gene, ORF3, is in a different reading frame embedded
within ORF1 and codes for a protein associated with apoptosis
(28). The significance of ORF3 with regard to the onset and
severity of PCVAD is still unknown (9).
The current model for the virion capsid structure locates the
arginine-rich N-terminal end of CP projecting inward, where it
interacts with the viral genome. Based on studies of another
circovirus, psittacine beak and feather disease virus, the argi-
nine-rich domain functions as a nuclear localization signal se-
quence, which shuttles the viral DNA across the nuclear pore
complex and into the nucleus, the site of PCV2 replication (10,
17, 29, 37).
Previous studies describing the humoral response following
PCV2 infection indicate that seroconversion occurs between
10 and 28 days postinfection or after vaccination (1, 35, 45).
There are reports that pigs with PMWS seroconvert later than
or produce a reduced antibody titer compared to subclinically
infected animals (5, 35). Another difference between subclin-
ical infection and PMWS is reduced neutralizing antibody
(NA) titers in PMWS pigs compared to those in subclinally
infected or vaccinated pigs (16, 45). There is no PCV2-based
model system that can reproduce PDNS. However, clinically
moribund pigs show a hyperimmune response leading to sig-
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nificant antibody production, which may contribute to immune
complex formation and PDNS (56).
For the purpose of mapping antibody epitopes in CP,
Lekcharoensuk et al. (26) used a panel of seven anti-CP mono-
clonal antibodies (MAbs), which were reacted with cells trans-
fected with infectious PCV chimeric DNA clones composed of
different combinations of PCV1 and PCV2a ORF2 sequences.
Immunoreactive regions were reported between residues 47
and 85, 165 and 200, and 200 and 233. Using overlapping
oligopeptides and sera from infected and immunized pigs,
Mahe´ et al. (33) described antibody-reactive regions between
amino acids 23 and 43, 71 and 85, 117 and 131, and 171 and 202
in CP. In a follow-up study, Truong et al. (55) identified amino
acids 117 to 131 as a dominant antibody recognition region.
Shang et al. (50) reported four regions in CP associated with
MAb recognition: amino acids 156 to 162, 175 to 192, 195 to
202, and 228 to 233.
The purpose of this study was to test the hypothesis that
sera from pigs experimentally infected or vaccinated or with
clinically diagnosed PCVAD produce different responses to
epitopes within PCV2 CP. The original intent was to identify
specific epitopes that could offer protection versus those
epitopes involved in immunopathogenesis. The epitope map-
ping methodology incorporated in this study is an extension of
previous work demonstrating that bacterially expressed CP
antigens react with antibody from PCV2-infected pigs (30, 38,
54). We extended this approach by evaluating the reactivities
of individual polypeptide fragments to different combinations
of epitopes followed by finer epitope mapping using overlap-
ping oligopeptides. The results describe several different rec-
ognition patterns within the different groups of pigs, including
the identification of a single epitope, 169-STIDYFQPNNKR,
which was preferentially recognized by pigs diagnosed with
PDNS and a subset of pigs experimentally infected with PCV2.
Alanine substitutions within CP(169–180) showed that Y-173,
F-174, Q-175, and K-179 amino acid residues contribute to
antibody recognition. The results from this study support the
notion of immune dysregulation, characterized by a hyperim-
mune response during PDNS and a diminished response dur-
ing PMWS. Furthermore, the methods incorporated in this
study provide a means for characterizing the immune response
upon vaccination, natural infection, and disease.
MATERIALS AND METHODS
Experimental PCV2 infection. All animal experiments were performed after
review and approval by Kansas State University Institutional Animal Use and
Biosafety committees. PCV2-negative pigs were derived from sows with low
PCV2 antibody titers (44). Upon entry into the challenge facility, pigs were
confirmed as negative for PCV2 DNA by PCR. At the time of virus challenge,
pigs were confirmed as negative for PCV2 DNA and PCV2 antibody as measured
by PCR and indirect fluorescent-antibody (IFA) assay, respectively. Pigs were
randomly assigned to one of seven groups, summarized in Table 1. The timeline
for vaccination and infection is diagrammed in Fig. 1. PCV2 vaccination was
performed using a two-dose commercial baculovirus-expressed PCV2 ORF2
product (Intervet) administered at 4 and 7 weeks of age according to label
instructions. Two weeks after the last vaccine dose, pigs were challenged with
PCV2 or PCV2 plus porcine reproductive and respiratory syndrome virus
(PRRSV). The PCV2 challenge inoculum consisted of a lymph node homoge-
nate from a pig with PMWS. Virus from the homogenate was titrated on swine
testicle (ST) cells in quadruplicate on a 96-well plate. Three days after infection,
the cells were fixed and stained with fluorescein isothiocyanate (FITC)-labeled
anti-PCV (Veterinary Medical Research and Development, Inc. [VMRD]). The
50% tissue culture infectious dose (TCID50) per ml was calculated according to
the Reed-Muench method (47). The concentration of virus in the challenge
homogenate was determined to be approximately 108 TCID50/ml. The inoculum
was negative for other common pathogens, such as porcine parvovirus and swine
influenza virus, but was positive for PRRSV. The homogenate was filtered to
remove bacteria. The rationale for using a homogenate was based on the inability
to obtain significant quantities of PCV2b in culture. PRRSV and other heat-
labile infectious agents were removed by heat inactivation at 60°C for 30 min.
Pigs were challenged intranasally with approximately 105 TCID50 of PCV2. For
dual challenge, 105 TCID50 of PRRSV was added back to the PCV2 inoculum.
All pigs were monitored for clinical signs and bled weekly. Sera were assayed for
PCV2 and PRRSV nucleic acid and virus-specific antibodies by the Kansas State
Veterinary Diagnostic Laboratory (KSVDL) using standard molecular and se-
rological diagnostic techniques. The experiment was terminated at 6 weeks after
virus challenge. Serum samples used for this study were obtained at the conclu-
sion of the experiment or 5 weeks after infection and 7 weeks after vaccination.
Selection of PCVAD pigs. PMWS and PDNS pigs were submitted as diagnostic
cases to the KSVDL. The diagnosis of PDNS or PMWS was made as previously
described (20). The PMWS pigs presented as emaciated with greatly enlarged
superficial inguinal lymph nodes. Histologically, secondary lymphoid organs were
almost completely depleted of lymphocytes. PCV2 antigen, as determined by
diagnostic immunohistochemistry (IHC) and PCR, was present in histological
lesions. PDNS pigs were identified by the presence of multifocal erythematous
lesions on the hindquarters. At the anatomical level, the kidneys were greatly
enlarged with cortical petechiae covering the kidney surface. The glomeruli were
swollen and fibrinous with necrosis of glomerular tufts. All pigs were confirmed
to be infected with a PCV2b virus. For the purposes of this study, 10 PDNS and
10 PMWS serum samples were selected.
PCV2 IFA and measurement of virus-neutralizing activity. Total PCV2 anti-
bodies were measured by indirect fluorescent-antibody (IFA) staining of infected
cells. Rapidly dividing ST cells, maintained in minimum essential medium
(MEM) with 10% fetal bovine serum (FBS) and antibiotics, were infected with
a laboratory isolate of PCV2 on 96-well plates. After 3 days, the plates were fixed
for 10 min in 80% acetone. An initial dilution of 1:40 was followed by 1:2
dilutions of each serum sample. Samples were diluted in phosphate-buffered
saline (PBS) with 5% FBS (PBS-FBS) and incubated with antigen for 2 h at room
temperature. After being washed in PBS, bound antibody was detected with
FITC-labeled anti-pig antibody (Jackson Labs) according to the manufacturer’s
recommendations. Plates were read on an inverted fluorescence microscope, and
titers were calculated as the reciprocal of the last serum dilution that showed
fluorescence staining. For measurement of virus-neutralizing activity, serial di-
lutions of serum in 100 l of cell culture medium were mixed with a constant
quantity of PCV2 (50 to 300 TCID50), incubated for 1 h at 37°C, and placed onto
FIG. 1. Timeline for experimental PCV2 vaccination and infec-
tion.
TABLE 1. Experimental infection/vaccination treatment groups
Group Description n
Treatment
Vaccine PCV2 PRRSV
1 Control 7   
2 Vaccine 7   
3 PRRSV 7   
4 PCV2 7   
5 PCV2/vaccine 7   
6 PCV2/PRRSV 7a   
7 PCV2/PRRSV/vaccine 7   
a Three of the seven pigs died following infection and were not subjected to
further study.
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four replicate wells of 1-day-old ST cells in 96-well plates. Plates were incubated
for 3 days at 37°C and then fixed and stained with FITC-labeled anti-PCV2
(VMRD). The log2 50% neutralizing activity (NA50) endpoint was calculated by
the method of Spearman and Karber (14a).
Cloning, expression, and purification of recombinant PCV2 polypeptides.
Previous immunological studies identified several antibody recognition sites in
CP, including at least one immunorelevant epitope (26, 33, 55). The epitope
recognition regions from these previous studies were combined and summarized
in Fig. 2. From these studies, we located four general antibody recognition
regions, labeled A (51 to 84), B (113 to 131), C (161 to 207), and D (228 to 233).
The CP amino acid sequence of the PCV2 used to infect pigs is the same PCV2b
genotype as the CP used to prepare polypeptide fragments (GenBank accession
no. HQ713495). CP was 99% identical to the CP of the PCV2b used for exper-
imental infection. There were two amino acid mutations: phenylalanine to as-
paragine at position 46 and phenylalanine to aspartic acid at position 115. To
prepare recombinant CP polypeptides, primers were designed to amplify regions
of CP containing one or more of the antibody recognition regions. The 5 ends
of the forward and reverse primers contained additional SacII and HindIII
restriction sites, respectively. The primers used for amplification and cloning of
the individual ORF2 cDNA fragments are listed in Table 2. PCR products were
cloned into PCR2.1 Topo (Promega), and plasmids were propagated in Esche-
richia coli. Plasmids were cut with SacII and HindIII, and the inserted DNA was
cloned in frame into the SacII and HindIII sites in the E. coli expression vector
pHUE (6). The pHUE vector is designed to yield a 6His ubiquitin fusion
protein. For recombinant protein expression, E. coli was grown in LB plus
ampicillin at 37°C until bacteria reached an optical density at 600 nm (OD600) of
0.4 to 0.6. Protein expression was induced by the addition of IPTG (isopropyl-
-D-thiogalactopyranoside; 1.0-g/ml final concentration), and cultures were
grown for an additional 4 h. Bacteria were harvested, and proteins were purified
using a PrepEase His-tagged protein purification kit (USB) according to the
manufacturer’s protocol. A modification of the procedure included the addition
of urea at a final concentration of 8 M to the bacterial disruption and Ni column
elution buffers. After elution from the nickel column, the protein-containing
fractions were concentrated on a 5,000-molecular-weight (MW)-cutoff spin col-
umn (Millipore), and total protein was measured using a protein assay (Bio-Rad)
according to the manufacturer’s protocol. The purified proteins were visualized
by SDS-PAGE.
CP polypeptide and oligopeptide ELISA. Commercially prepared 20-mer
oligopeptides (21st Century Biochemicals) were conjugated to bovine serum
albumin (BSA) by the manufacturer. For the purpose of conjugation to BSA, a
cysteine was added to the N- or C-terminal end of the oligopeptide. Each CP
polypeptide or BSA-conjugated oligopeptide was diluted to 4 g/ml in 0.05 M
carbonate binding buffer (pH 9.6), and 100 l was added to each well of an
enzyme-linked immunosorbent assay (ELISA) plate (Costar). Antigen-coated
ELISA plates were incubated at 4°C for approximately 15 h. Wells were washed
three times with PBS-0.01% Tween 20 (PBST) and then blocked for at least 1 h
at room temperature in PBS with 10% goat serum (PBS-GS). Next, 100 l of
1:100 dilutions of pig sera in PBS-GS was added to the plates and then incubated
for 2 h at room temperature. After being washed with PBST, 100 l of peroxi-
dase-labeled goat anti-swine antibody (Accurate Chemical & Scientific Corp.)
diluted 1:2,000 in PBS-GS was added to each well, and incubation continued for
1 h at room temperature. After extensive washing with PBST, peroxidase activity
was detected by addition of 100 l of the chromogenic substrate ABTS [2,2-
azinobis(3-ethylbenzthiazolinesulfonic acid); KPL]. Following a 20-min incuba-
tion away from light, absorbance values were read at 405 nm using a Maxline
microplate reader (Molecular Devices Corporation).
Binding ratio calculation. To compare results across ELISA plates, each
ELISA plate included an internal positive control, which consisted of wells
coated with the largest CP polypeptide [CP(43–233)] incubated with serum from
a PDNS pig with a high PCV2 antibody titer. The antibody binding ratio was
calculated as the A405 value of the test sample minus background divided by the
A405 value of the internal positive control minus background. Antibody binding
ratios for samples and control were derived from a 1:100 dilution.
FIG. 2. Locations of immunoreactive regions in PCV2 CP. Underlined regions in the PCV2a genotype peptide sequence show the locations of
the immunoreactive regions described by Lekcharoensuk et al. (26) using MAbs prepared against whole purified virus (strain ISU 31, GenBank
accession number AJ223185). The underlined regions in the PCV2b genotype sequence (GenBank accession number AF201311) summarize the
results obtained from the pepscan analysis by Mahe´ et al. (33). The epitope maps are combined to yield the shaded peptide sequences, identified
as epitope regions A, B, C, and D. Amino acids in bold show the location of an immunodominant region described by Truong et al. (55). The box
identifies the putative receptor binding region described in the work of Misinzo et al. (36).
TABLE 2. Primer sequences used for preparing CP polypeptidesa
CP region
(amino acids) Forward primer Reverse primer
43–135 5CCGCGGTGGTAATGGCATCTTCAACA 5AAGCTTTTAGGCTGTGGCCTTTGATA
91–233 5CCGCGGTGGAGTGCCCTTTGAATACT 5GCGCAAGCTTTTAAGGGTTAAGTGGC
136–233 5CCGCGGTGGACTCACCTATGACCCCT 5GCGCAAGCTTTTAAGGGTTAAGTGGC
91–160 5CCGCGGTGGAGTGCCCTTTGAATACT 5AAGCTTTTAGTAGCGGGTGTGGTAGC
160–233 5CTCCGCGGTGGATACTTTACCCCCAA 5GCGCAAGCTTTTAAGGGTTAAGTGGC
43–160 5CCGCGGTGGTAATGGCATCTTCAACA 5AAGCTTTTAGTAGCGGGTGTGGTAGC
43–180 5CCGCGGTGGTAATGGCATCTTCAACA 5GCGCAAGCTTTTAATCTTTTGTTGTT
43–233 5CCGCGGTGGTAATGGCATCTTCAACA 5GCGCAAGCTTTTAAGGGTTAAGTGGC
a Additional SacII and HindIII restriction sites are underlined.
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Field vaccination study. For the purpose of determining antibody responses to
CP(43–233) and CP(169–180) before and after vaccination, samples were col-
lected from a 150-head sow source herd that was being vaccinated for the first
time. The source of the vaccine was a baculovirus-expressed ORF2 PCV2 vac-
cine, the same vaccine that was used to experimentally vaccinate pigs in the
experimental study. Pigs were vaccinated at 3 and 6 weeks of age according to the
vaccine label instructions. Blood was collected from 33 randomly selected
3-week-old pigs derived from 10 different dams. The same pigs were bled a
second time at 16 weeks of age, or 10 weeks after administration of the last
vaccine dose. Sera were reacted with CP(43–233) and CP(169–180) in an ELISA
as previously described.
RESULTS
Expression and immunoreactivity of CP polypeptides. The
largest CP fragment contained the full-length protein minus
the first 42 amino acid residues. The removal of the first 42
amino acids, which contain the arginine-rich domain, increases
polypeptide expression in bacteria (54). Analysis of CP(43–
233) by SDS-PAGE showed a single protein band that mi-
grated at the predicted molecular weight (data not shown).
The remaining ORF2 constructs, CP(43–135), CP(43–160),
CP(43–180), CP(91–160), CP(160–233), CP (135–233), and
CP(91–233), were cloned into pHUE, expressed, and affinity
purified. Unlike CP(43–233), the smaller polypeptides were
retained within the bacteria as insoluble inclusion bodies.
Therefore, 8 M urea was added to the extraction and purifi-
cation buffers. SDS-PAGE confirmed that all recombinant
polypeptides were expressed and possessed the predicted size
(data not shown). CP polypeptides were applied as a coating
directly to ELISA plates as His-ubiquitin fusion proteins. As
mentioned above, urea was required to solubilize the polypep-
tides, with the exception of the largest polypeptide, CP(43–
233). The synthesis of a truncated protein combined with the
presence of urea likely disrupted conformational epitopes
within CP; however, all polypeptides demonstrated the ability
to react with sera from diseased and infected pigs (see below).
The first antibody measurements were performed on sera
from experimentally infected pigs (described in Table 1). To
reduce variation in results across ELISA plates, each ELISA
plate included an internal positive-control serum reacted with
CP(43–233). The results in Fig. 3A showed only low binding
ratios for the uninfected control pigs. The same serum samples
were also negative for PCV2 antibody as measured by IFA
assay and negative for PCV2 DNA by PCR (data not shown).
The results confirmed that the control pigs remained negative
for PCV2 infection during the experiment. The antibody bind-
ing ratios for pigs infected with PCV2 and PCV2-PRRSV are
shown in Fig. 3B. Since there was no significant difference in
the antibody responses between the pigs infected with PCV2
and those dually infected with PCV2-PRRSV, the data for the
two groups were combined. All PCV2-challenged pigs were
positive for PCV2 infection by PCR and for PCV2 antibody by
IFA assay, which confirmed that all pigs were productively
infected. PRRSV reverse transcription-PCR (RT-PCR) and
serology confirmed that all dual-infected pigs were produc-
tively infected with PRRSV. Seven of the 11 pigs in this group
showed no clinical evidence of PDNS or PMWS. Three pigs in
the dual-challenged group died and were not included in the
study. The remaining pigs showed some disease signs, includ-
ing reduced weight gain and accumulation of PCV2 antigen in
lymph nodes (data not shown). As shown in Fig. 3B, the PCV2
group showed measurable antibody activity against all poly-
peptides by at least one pig; however, the highest mean binding
ratio was obtained for the full-length CP(43-233) polypeptide
and the lowest for CP(43-135), CP(43-160), and CP(91-160).
The remaining polypeptides, CP(91-233), CP(135-233),
CP(160-233), and CP(43-180), possess mean ratios that were
intermediate between those of CP(43-233) and the low-re-
sponding polypeptides. The responses for the seven pigs re-
ceiving only the PCV2 vaccine are shown in Fig. 3C. All vac-
cinated pigs were positive for PCV2 antibody by IFA assay and
were confirmed to be negative for PCV2 by PCR (data not
shown). The highest binding ratios were observed for the
FIG. 3. Immunoreactivities of bacterium-expressed polypeptides
with sera from experimentally PCV2-infected and vaccinated pigs. The
ELISA results show the responses of sera from PCV2-negative (A),
PCV2-infected (B), and CP-vaccinated (C) pigs obtained at 5 weeks
after experimental infection with PCV2 or 7 weeks after vaccination as
described in the timeline shown in Fig. 1. The antibody binding ratio
was calculated as described in Materials and Methods. The open cir-
cles show the responses of individual pigs. The means and standard
deviations are represented by horizontal lines. Means with the same
lowercase letter do not significantly differ as determined by the Stu-
dent-Newman-Keuls method (P  0.05).
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CP(43-233) polypeptide, with only background levels of bind-
ing against the smaller CP fragments. The only exception was
CP(43-180), which showed a small, but significant, increase in
binding relative to the other small polypeptide fragments. In
order to demonstrate that vaccinated pigs were protected, 14
vaccinated pigs were challenged with PCV2 (seven pigs) or
PCV2 plus PRRSV (seven pigs). All challenged pigs remained
clinically normal with no mortality and were negative for PCV2
DNA in serum (data not shown).
Serological responses of pigs with PCVAD. Currently, there
are no PCV2 experimental infection models that consistently
reproduce all of the elements of PMWS or PDNS. Therefore,
sera from pigs submitted to the KSVDL with a diagnosis of
PCVAD were evaluated for recognition of CP polypeptides.
Even though PCV2 may not be the proximal cause of PDNS
(25), pigs with PDNS typically possess high levels of PCV2
antibodies (56). As shown in Fig. 4A, 9 of 10 PDNS pigs
possessed high binding activity against CP(43–233). Overall,
relatively high levels of antibody binding were observed for
seven of the eight polypeptides, with the highest mean anti-
body binding ratio being that against the smallest polypeptide,
CP(160–233). Significantly lower binding ratios were observed
for CP(43–135) and CP(43–160). The results for sera from 10
pigs diagnosed with PMWS are shown in Fig. 4B. Unlike the
PDNS pigs, overall binding ratios against the CP fragments
were relatively low for a majority of the pigs. Two of the 10 pigs
showed elevated binding ratios against CP(43–233), while four
pigs exhibited only background activity against CP(43–233),
and the remaining four showed intermediate activities. The
overall low binding ratios against CP(43–233) likely reflect
decreased antibodies as a result of the overall depletion of
lymphocytes, which occurs during end-stage PMWS. Responses
against the other oligopeptides were also variable, except for
CP(43–135) and CP(43–160), which were negative for binding.
A summary of the antibody binding activities of the different
groups of pigs against the different CP fragments is presented
in Table 3. For PCV2-infected, PMWS, and PDNS pigs, the
highest levels of antibody binding were obtained primarily for
CP polypeptides that contained epitope C (Fig. 2).
Pepscan mapping of the C-terminal region of CP. Further
studies were performed to determine the smallest oligopeptide
recognized by PCV2-infected pigs. Based on the results of
Table 3, 20-mer oligopeptides, with 10 overlapping residues,
spanning epitope C and the flanking region (residues 141 to
FIG. 4. Immunoreactivities of PCV2 CP polypeptides with sera
from pigs with PDNS and PMWS. The same ELISA method described
in the Fig. 3 legend was used to assess antibody activity in sera from
pigs diagnosed with PDNS (A) or PMWS (B). The open circles show
the responses of individual pigs. The horizontal lines show means and
standard deviations. Means with the same lowercase letter do not
significantly differ as determined by the Student-Newman-Keuls
method (P  0.05).
TABLE 3. Summary of antibody responses to PCV2 capsid polypeptides
Name Epitope region(s)
Relative binding activitya
PC Vx PM PD
43–233    
43–135    
43–160    
91–160    
43–180    
160–233    
135–233    
91–233    
a PC, PCV2 infected; Vx, vaccinated; PM, PMWS; PD, PDNS; , no measurable binding activity; , low binding activity; , intermediate binding activity; ,
high binding activity; , very high binding activity.
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200), were prepared and reacted with sera from PCV2-infected
and PDNS pigs. The results for the experimentally infected
PCV2 pigs showed a large variation in binding activity. Closer
inspection of the data revealed that pigs could be divided into
two groups. For instance, as presented in Fig. 5A, 4 of the 11
serum samples showed minimal binding activity against all
oligopeptides (gray bars), similar to the responses of vacci-
nated and uninfected control pigs (data not shown). The re-
maining PCV2-infected pigs exhibited a pattern shown by the
black bars, with relatively high activity against the CP(161–180)
and CP(169–188) oligopeptides and lower binding activity
against the flanking oligopeptides. The combined region
CP(161–188) is within the epitope C region. Two 12-mer oli-
gopeptides covering the region overlapped by CP(161–180)
and CP(169–188) were prepared and tested for antibody bind-
ing. The BSA-conjugated oligopeptides, CP(169-180C) and
CP(169-180N), were constructed with an aminohexonic acid
(Ahx) spacer added to the C- or N-terminal end, respectively.
The spacer fragment was designed to increase antibody acces-
sibility by extending the oligopeptide beyond the surface of the
BSA molecule. Both oligopeptides showed binding activities
similar to those of the CP(161–180) and CP(169–188) parent
oligopeptides. Results for sera from PDNS pigs are shown in
Fig. 5B. Similar to the responses shown by black bars in Fig.
5A, the highest binding activities for the PDNS pigs were
against CP(161–180), CP(169–188), and CP(169–180).
Alanine scanning mutagenesis in CP(169–180). To identify
the individual amino acids that contributed to antibody recog-
nition within CP(169–180), single alanine substitutions were
made along the CP(169–180) peptide sequence, 169-STIDY-
FQPNNKR-180. The results for the subset of experimentally
infected PCV2 pigs that showed high binding against CP(169–
180) in Fig. 5A are presented in Fig. 6A. The results showed
reduced binding for oligopeptides with alanine substitutions at
tyrosine-173, phenylalanine-174, glutamine-175, and lysine-
179. Similar alanine scanning results were obtained for sera
from PDNS pigs (Fig. 6B).
Four hundred sixty-two CP(169–180) peptide sequences, ob-
tained from GenBank and diagnostic lab submissions, were
analyzed for amino acid differences. The results, presented
below Fig. 6A, showed that 45 of the 462 sequences possessed
changes within CP(169–180): all were single amino acid sub-
stitutions. For those residues that contributed to binding, ty-
rosine-173, phenylalanine-174, glutamine-175, and lysine-179,
there were only two amino acid substitutions. Therefore, the
core peptide region that forms the epitope within CP(169–180)
is highly conserved.
Virus-neutralizing activity in PCV2-infected and vaccinated
pigs. Virus-neutralizing activity in serum samples from the
same PCV2 pigs in Fig. 3B and vaccinated pigs in Fig. 3C is
shown in Fig. 7. The mean total antibody level for PCV2-
infected pigs (IFA titer  6.7), as measured by IFA assay, was
almost twice the level of the mean value for the vaccinated pigs
FIG. 5. Immunoreactivities of pig sera with CP oligopeptides.
(A) Antibody responses of experimentally infected pigs against a series
of 20-mer overlapping oligopeptides that cover residues 141 to 200 of
the PCV2 CP. The gray bars show the means and standard deviations
for a subset of four pigs that possessed low antibody levels of binding
against all oligopeptides. The black bars show the means and standard
deviations for the remaining six pigs. (B) Responses of sera from
PDNS pigs. The results show the mean and 1 standard deviation of the
antibody binding ratio for each group of pigs.
FIG. 6. Alanine scanning mutagenesis. (A) Mean and standard de-
viation results for the same six pigs as those shown in Fig. 5A (black
bars) that recognized CP(169–180). BSA-conjugated oligopeptides
that possessed single alanine substitutions were tested. The numbers
below panel A show the numbers of amino acid substitutions found in
a comparison of 462 peptide sequences obtained from GenBank and
diagnostic lab submissions. (B) Alanine scanning results for the same
PDNS pigs as those shown in Fig. 5B.
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(IFA titer  5.8). In contrast, the mean NA level for vacci-
nated pigs (log2 NA50  2.8) was approximately four times
higher than the mean level obtained from sera of PCV2-in-
fected pigs (log2 NA50  1.6).
Serological response to CP(169–180) following PCV2 vacci-
nation in the field. We determined the antibody responses to
CP(43–233) and CP(169–180) before and after vaccination of a
small pig herd that had a history of clinically apparent PCV2
infection, which was confirmed by serology and PCR (data not
shown). The results, summarized in Fig. 8, showed that the
antibody responses of the 3-week-old pigs were directed
against both CP(43–233) and CP(169–180) oligopeptides. The
presence of CP-specific antibody in prevaccination pigs is
primarily the result of maternally derived antibodies from
dams that had been naturally infected with PCV2 (19). At 16
weeks of age (10 weeks after the second vaccine dose), the
pattern of antigen recognition changed, with the response
against CP(169–180) greatly diminished relative to that
against CP(43–233). The effectiveness of vaccination was con-
firmed by the disappearance of clinical disease from the herd
and by the decreased prevalence of PCR-positive serum sam-
ples. Together, the results illustrate a pattern showing the
initial presence of antibodies derived from natural infection,
which were replaced with CP(43–233)-specific antibodies gen-
erated in response to vaccination with CP.
DISCUSSION
Previous studies of humoral immunity during PCV2 infec-
tion have primarily focused on mapping antigenic regions of
CP, including the characterization of immunorelevant epitopes
(26, 33, 55). The present study describes differences in the
antibody responses toward PCV2 CP immunoreactive regions
following vaccination and experimental infection and during
severe disease. The results illustrate the complexity of the
immune response during PCV2 infection while providing in-
formation on the immunological basis for protection during
vaccination and the initiation of immunopathogenesis. Analy-
sis of antibody reactivities of infected, vaccinated, and PCVAD
pigs against individual CP polypeptide fragments and oligo-
peptides identified at least four unique antibody recognition
patterns, which are summarized in Table 3. The first pattern is
illustrated by pigs with severe PMWS. Overall, there was a
decreased reactivity to all CP polypeptide antigens (Fig. 4B).
This outcome is consistent with the immune suppression asso-
ciated with PMWS, a disease syndrome characterized by an
almost complete depletion of lymphocytes with a correspond-
ing loss or severe dysregulation of immune function (13). Im-
munohistochemical staining of PMWS lymph nodes typically
shows large accumulations of PCV2 antigen (8). Presumably,
dividing lymphocytes, activated in response to infection or
other immune stimuli, become a primary target for PCV2
replication. Cytopathogenesis in lymphocytes is attributed to
the function of PCV2 ORF3, which is not required for virus
replication in culture but has been linked to apoptosis (21, 22,
28). In sharp contrast, pigs with clinically apparent PDNS
showed high reactivity to all CP polypeptide fragments (Fig. 4),
including the oligopeptide CP(169–180) (Fig. 5B). This out-
come is consistent with hyperactive humoral response and im-
mune complex formation. Pathogenesis is linked to the depo-
sition of antigen-antibody complexes in the kidney and other
organs followed by the activation of complement (56). The role
that PCV2 plays in PDNS remains unclear. Krakowka et al.
(25) reported the induction of PDNS in gnotobiotic pigs after
infection with a group 1 torque teno virus (TTV) and PRRSV.
To date, there are no models of PCV2 infection that reproduce
PDNS. One likely possibility is that PCV2 infection may not be
the proximal cause of PDNS but may play a role in the evolu-
tion of the disease process and expression of full-blown dis-
ease.
A third pattern of antibody recognition was found in the
responses of pigs experimentally infected with PCV2. The re-
sults showed the highest antibody response to CP(43–233)
followed by reactivity with polypeptides that contained epitope
FIG. 8. Recognition of CP(43–233) and CP(169–180) in a herd
before and after PCV2 vaccination. Results are from a herd vaccinated
for PCV2 for the first time. Samples were tested when pigs received the
first dose of vaccine (3 weeks of age), and the same pigs were tested at
16 weeks of age, or 10 weeks after the second vaccine dose. The results
are shown as the means and standard deviations for 33 pigs reacted
with CP(43–233) and CP(169–180) oligopeptides. All samples were
assayed on a single plate, and results (vertical axis) are presented as
A405 values. The oligopeptides CP(169-180N) and CP(169-180C) were
linked to BSA via the N- or C-terminal end of the oligopeptide,
respectively.
FIG. 7. Total and neutralizing antibody responses following vacci-
nation and infection. Serum samples from PCV2-infected (PC) pigs
(Fig. 3B) and PCV2-vaccinated (VX) pigs (Fig. 3C) were tested for the
presence of total antibody (IFA) and neutralizing activity (NA). Open
circles represent values for individual pigs, and the horizontal bars
represent the mean value for each group.
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C. A dichotomy in the response to the epitope C region was
evident from the oligopeptide mapping results, in which PCV2
pigs could be divided into two groups: those that produced a
response similar to that of PDNS pigs and recognized CP(169–
180) and those that responded similarly to vaccinates. Finally,
a fourth antibody response pattern was found in pigs vacci-
nated with a baculovirus-expressed CP antigen. Vaccinated
pigs almost exclusively recognized the largest polypeptide,
CP(43–233), and showed much lower responses to smaller
polypeptides, including those polypeptide fragments that con-
tained epitope C (Fig. 3C). This pattern of antibody recogni-
tion suggests that vaccination produces antibodies that primar-
ily recognize a single large conformational epitope. Evidence
for the protective nature of this response was found in the
complete protection of vaccinated pigs challenged with PCV2
or with PCV2 and PRRSV and suggests that vaccination with
only CP is sufficient to deliver sterilizing immunity.
The principal difference between PCVAD and vaccinated
pigs localized to CP(169–180), within epitope C. PDNS pigs
and a subset of PCV2 pigs preferentially recognized CP(169–
180). To further demonstrate the specific nature of the recog-
nition, alanine scanning mutagenesis identified specific resi-
dues as important for antibody recognition. Furthermore, the
key amino acid residues involved in antibody binding are
highly conserved among PCV2 isolates. The significance of
this epitope in disease progression is not entirely clear. How-
ever, the results suggest that antibodies directed against this
epitope are not involved in immune protection. Protection
from infection and disease is likely dependent on antibodies
directed against a single, conformational epitope. The results
support the hypothesis that antibodies preferentially directed
against epitope C are nonprotective and signal the initial im-
mune defect that leads to disease. One possibility is that
epitope C functions as a decoy epitope, allowing PCV2 to
evade humoral immunity by focusing the antibody response
toward a nonprotective epitope. Evidence for this possibility is
found in the total and neutralizing antibody responses of
PCV2-infected versus CP-vaccinated pigs (Fig. 7). Even
though the total PCV2 antibody response of infected pigs was
almost twice the response of vaccinated pigs, the mean neu-
tralizing activity for the vaccinated group was almost four times
that of the infected group. Therefore, the apparent paradox of
decreased neutralizing activity in the face of an overall robust
humoral response can be resolved if the response is directed
toward nonneutralizing epitopes. The diversion of humoral
immunity away from the larger neutralizing epitope is a strat-
egy that has been proposed for HIV and PRRSV (27, 46).
One interesting aspect of PCV2 infection is that only a
subpopulation of infected pigs go on to develop full-blown
disease, while other infected pigs remain unaffected. The
mixed antibody response of PCV2-infected pigs provides in-
sight into a possible mechanism for differences in disease sus-
ceptibility within the same population of PCV2-infected pigs.
For example, those pigs that respond to PCV2 in a manner
similar to that of pigs following vaccination produce an effec-
tive antibody response that results in virus clearance and pro-
tection. In contrast, those pigs that produce a response similar
to PDNS pigs, i.e., against nonprotective epitopes, are more
susceptible to prolonged virus replication and disease.
A practical application of the results from this study is illus-
trated by the data obtained for herd vaccination, shown in Fig.
8. Prior to vaccination, maternally derived antibody (MDA)
acquired during natural infection showed reactivity to both
CP(43–233) and CP(169–180), a pattern similar to that in ex-
perimental PCV2 infection. After vaccination and decay of
MDA, the antibody recognition pattern switched to recogni-
tion of only CP(43–233). Therefore, differential recognition of
CP(43–233) and CP(169–180) provides the basis for diagnostic
approaches that can assess the level of protective antibody in a
vaccinated herd, as well as methods that can differentiate in-
fected from vaccinated animals (DIVA).
ACKNOWLEDGMENTS
This work was supported by National Pork Board grant 06-073 and
USDA NRI grant 2009-35204-05290.
REFERENCES
1. Allan, G. M., and J. A. Ellis. 2000. Porcine circoviruses: a review. J. Vet.
Diagn. Invest. 12:3–14.
2. Allan, G. M., et al. 1999. Experimental reproduction of severe wasting
disease by co-infection of pigs with porcine circovirus and porcine parvovi-
rus. J. Comp. Pathol. 121:1–11.
3. Allan, G., et al. 2003. Reproduction of postweaning multisystemic wasting
syndrome in pigs experimentally inoculated with a Swedish porcine circovi-
rus 2 isolate. J. Vet. Diagn. Invest. 15:553–560.
4. Blanchard, P., et al. 2003. Protection of swine against post-weaning multi-
systemic wasting syndrome (PMWS) by porcine circovirus type 2 (PCV2)
proteins. Vaccine 21:4565–4575.
5. Bolin, S. R., W. C. Stoffregen, G. P. Nayar, and A. L. Hamel. 2001. Postwean-
ing multisystemic wasting syndrome induced after experimental inoculation
of cesarean-derived, colostrum-deprived piglets with type 2 porcine circovi-
rus. J. Vet. Diagn. Invest. 13:185–194.
6. Catanzariti, A., T. A. Soboleva, D. A. Jans, P. G. Board, and R. T. Baker.
2004. An efficient system for high-level expression and easy purification of
authentic recombinant proteins. Protein Sci. 13:1331–1339.
7. Chae, C. 2005. A review of porcine circovirus 2-associated syndromes and
diseases. Vet. J. 169:326–336.
8. Chae, C. 2004. Postweaning multisystemic wasting syndrome: a review of
aetiology, diagnosis and pathology. Vet. J. 168:41–49.
9. Chaiyakul, M., K. Hsu, R. Dardari, F. Marshall, and M. Czub. 2010. Cyto-
toxicity of ORF3 proteins from a nonpathogenic and a pathogenic porcine
circovirus. J. Virol. 84:11440–11447.
10. Cheung, A. K., and S. R. Bolin. 2002. Kinetics of porcine circovirus type 2
replication. Arch. Virol. 147:43–58.
11. Cheung, A. K. 2003. Comparative analysis of the transcriptional patterns of
pathogenic and nonpathogenic porcine circoviruses. Virology 310:41–49.
12. Cheung, A. K. 2003. Transcriptional analysis of porcine circovirus type 2.
Virology 305:168–180.
13. Darwich, L., J. Segale´s, and E. Mateu. 2004. Pathogenesis of postweaning
multisystemic wasting syndrome caused by porcine circovirus 2: an immune
riddle. Arch. Virol. 149:857–874.
14. Dorr, P. M., G. W. Almond, S. R. Wayne, and W. A. Gebreyes. 2007. Epi-
demiologic assessment of porcine circovirus type 2 coinfection with other
pathogens in swine. J. Am. Vet. Med. Assoc. 230:244–250.
14a.Finney, D. J. 1964. The Spearman-Karber method, p. 524–530. In D. J.
Finney (ed.), Statistical method in biological assay, 2nd ed. Charles Griffin,
London, United Kingdom.
15. Fort, M., et al. 2008. Porcine circovirus type 2 (PCV2) vaccination of con-
ventional pigs prevents viremia against PCV2 isolates of different genotypes
and geographic origins. Vaccine 26:1063–1071.
16. Fort, M., A. Olvera, M. Sibila, J. Segale´s, and E. Mateu. 2007. Detection of
neutralizing antibodies in postweaning multisystemic wasting syndrome
(PMWS)-affected and non-PMWS-affected pigs. Vet. Microbiol. 125:244–
255.
17. Heath, L., A. Williamson, and E. P. Rybicki. 2006. The capsid protein of beak
and feather disease virus binds to the viral DNA and is responsible for
transporting the replication-associated protein into the nucleus. J. Virol.
80:7219–7225.
18. Hesse, R., M. Kerrigan, and R. R. R. Rowland. 2008. Evidence for recom-
bination between PCV2a and PCV2b in the field. Virus Res. 132:201–207.
19. Horlen, K. P., et al. 2008. A field evaluation of mortality rate and growth
performance in pigs vaccinated against porcine circovirus type 2. J. Am. Vet.
Med. Assoc. 232:906–912.
20. Horlen, K. P., et al. 2007. A cluster of farms experiencing severe porcine
circovirus associated disease: clinical features and association with the
PCV2b genotype. J. Swine Health Prod. 15:270–278.
756 TRIBLE ET AL. CLIN. VACCINE IMMUNOL.
21. Juhan, N. M., T. LeRoith, T. Opriessnig, and X. J. Meng. 2010. The open
reading frame 3 (ORF3) of porcine circovirus type 2 (PCV2) is dispensable
for virus infection but evidence of reduced pathogenicity is limited in pigs
infected by an ORF3-null PCV2 mutant. Virus Res. 147:60–66.
22. Karuppannan, A. K., et al. 2009. Attenuation of porcine circovirus 2 in SPF
piglets by abrogation of ORF3 function. Virology 383:338–347.
23. Krakowka, S., et al. 2001. Activation of the immune system is the pivotal
event in the production of wasting disease in pigs infected with porcine
circovirus-2 (PCV-2). Vet. Pathol. 38:31–42.
24. Krakowka, S., et al. 2000. Viral wasting syndrome of swine: experimental
reproduction of postweaning multisystemic wasting syndrome in gnotobiotic
swine by coinfection with porcine circovirus 2 and porcine parvovirus. Vet.
Pathol. 37:254–263.
25. Krakowka, S., et al. 2008. Evaluation of induction of porcine dermatitis and
nephropathy syndrome in gnotobiotic pigs with negative results for porcine
circovirus type 2. Am. J. Vet. Res. 69:1615–1622.
26. Lekcharoensuk, P., et al. 2004. Epitope mapping of the major capsid protein
of type 2 porcine circovirus (PCV2) by using chimeric PCV1 and PCV2.
J. Virol. 78:8135–8145.
27. Lin, G., and P. L. Nara. 2007. Designing immunogens to elicit broadly
neutralizing antibodies to the HIV-1 envelope glycoprotein. Curr. HIV Res.
5:514–541.
28. Liu, J., I. Chen, and J. Kwang. 2005. Characterization of a previously un-
identified viral protein in porcine circovirus type 2-infected cells and its role
in virus-induced apoptosis. J. Virol. 79:8262–8274.
29. Liu, Q., S. K. Tikoo, and L. A. Babiuk. 2001. Nuclear localization of the
ORF2 protein encoded by porcine circovirus type 2. Virology 285:91–99.
30. Liu, Q., P. Willson, S. Attoh-Poku, and L. A. Babiuk. 2001. Bacterial expres-
sion of an immunologically reactive PCV2 ORF2 fusion protein. Protein
Expr. Purif. 21:115–120.
31. Lyoo, K., et al. 4 August 2010. Comparative efficacy of three commercial
PCV2 vaccines in conventionally reared pigs. Vet. J. [Epub ahead of print.]
doi:10.1016/j.tvjl.2010.06.015.
32. Ma, C., et al. 2007. Evidence for recombination in natural populations of
porcine circovirus type 2 in Hong Kong and mainland China. J. Gen. Virol.
88:1733–1737.
33. Mahe´, D., et al. 2000. Differential recognition of ORF2 protein from type 1
and type 2 porcine circoviruses and identification of immunorelevant
epitopes. J. Gen. Virol. 81:1815–1824.
34. Mankertz, A., and B. Hillenbrand. 2001. Replication of porcine circovirus
type 1 requires two proteins encoded by the viral rep gene. Virology 279:
429–438.
35. Meerts, P., et al. 2006. Correlation between the presence of neutralizing
antibodies against porcine circovirus 2 (PCV2) and protection against rep-
lication of the virus and development of PCV2-associated disease. BMC Vet.
Res. 2:6.
36. Misinzo, G., P. L. Delputte, P. Meerts, D. J. Lefebvre, and H. J. Nauwynck.
2006. Porcine circovirus 2 uses heparan sulfate and chondroitin sulfate B
glycosaminoglycans as receptors for its attachment to host cells. J. Virol.
80:3487–3494.
37. Nakai, K., and M. Kanehisa. 1992. A knowledge base for predicting protein
localization sites in eukaryotic cells. Genomics 14:897–911.
38. Nawagitgul, P., et al. 2000. Open reading frame 2 of porcine circovirus type
2 encodes a major capsid protein. J. Gen. Virol. 81:2281–2287.
39. Olvera, A., M. Cortey, and J. Segale´s. 2007. Molecular evolution of porcine
circovirus type 2 genomes: phylogeny and clonality. Virology 357:175–185.
40. Opriessnig, T., et al. 2006. Evidence of breed-dependent differences in
susceptibility to porcine circovirus type-2-associated disease and lesions. Vet.
Pathol. 43:281–293.
41. Opriessnig, T., N. E. McKeown, E. Zhou, X. Meng, and P. G. Halbur. 2006.
Genetic and experimental comparison of porcine circovirus type 2 (PCV2)
isolates from cases with and without PCV2-associated lesions provides evi-
dence for differences in virulence. J. Gen. Virol. 87:2923–2932.
42. Opriessnig, T., A. R. Patterson, D. M. Madson, N. Pal, and P. G. Halbur.
2009. Comparison of efficacy of commercial one dose and two dose PCV2
vaccines using a mixed PRRSV-PCV2-SIV clinical infection model 2-3-
months post vaccination. Vaccine 27:1002–1007.
43. Opriessnig, T., et al. 2004. Experimental reproduction of postweaning mul-
tisystemic wasting syndrome in pigs by dual infection with Mycoplasma
hyopneumoniae and porcine circovirus type 2. Vet. Pathol. 41:624–640.
44. Opriessnig, T., S. Yu, and E. L. Thacker. 2004. Derivation of porcine circo-
virus type 2-negative pigs from positive breeding herds. J. Swine Health
Prod. 12:186–191.
45. Opriessnig, T., X. Meng, and P. G. Halbur. 2007. Porcine circovirus type 2
associated disease: update on current terminology, clinical manifestations,
pathogenesis, diagnosis, and intervention strategies. J. Vet. Diagn. Invest.
19:591–615.
46. Ostrowski, M., et al. 2002. Identification of neutralizing and nonneutralizing
epitopes in the porcine reproductive and respiratory syndrome virus GP5
ectodomain. J. Virol. 76:4241–4250.
47. Reed, J., and H. Muench. 1938. A simple method of estimating fifty percent
endpoints. Am. J. Hyg. 27:493–497.
48. Segale´s, J., et al. 2008. PCV-2 genotype definition and nomenclature. Vet.
Rec. 162:867–868.
49. Segale´s, J., G. M. Allan, and M. Domingo. 2005. Porcine circovirus diseases.
Anim. Health Res. Rev. 6:119–142.
50. Shang, S., et al. 2009. Fine mapping of antigenic epitopes on capsid proteins
of porcine circovirus, and antigenic phenotype of porcine circovirus type 2.
Mol. Immunol. 46:327–334.
51. Shen, H. G., et al. 2010. Comparison of commercial and experimental por-
cine circovirus type 2 (PCV2) vaccines using a triple challenge with PCV2,
porcine reproductive and respiratory syndrome virus (PRRSV), and porcine
parvovirus (PPV). Vaccine 28:5960–5966.
52. Sorden, S. D. 2000. Update on porcine circovirus and postweaning multisys-
temic wasting syndrom (PMWS). Swine Health Prod. 8:133–138.
53. Thomson, J. R., R. J. Higgins, W. J. Smith, and S. H. Done. 2002. Porcine
dermatitis and nephropathy syndrome. Clinical and pathological features of
cases in the United Kingdom (1993–1998). J. Vet. Med. A Physiol. Pathol.
Clin. Med. 49:430–437.
54. Trundova, M., and V. Celer. 2007. Expression of porcine circovirus 2 ORF2
gene requires codon optimized E. coli cells. Virus Genes 34:199–204.
55. Truong, C., et al. 2001. Identification of an immunorelevant ORF2 epitope
from porcine circovirus type 2 as a serological marker for experimental and
natural infection. Arch. Virol. 146:1197–1211.
56. Wellenberg, G. J., N. Stockhofe-Zurwieden, M. F. de Jong, W. J. A. Boersma,
and A. R. W. Elbers. 2004. Excessive porcine circovirus type 2 antibody titres
may trigger the development of porcine dermatitis and nephropathy syn-
drome: a case-control study. Vet. Microbiol. 99:203–214.
VOL. 18, 2011 PCV2 EPITOPES 757
